661470-52-6

Basic information

• Product Name: Morpholine, 2-(phenoxymethyl)-, (2S)-
• CAS NO: 661470-52-6
• Molecular Formula: C11H15NO2
• Molecular Weight: 193.246
• Mol File: 661470-52-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Morpholine, 2-(phenoxymethyl)-, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Morpholine, 2-(phenoxymethyl)-, (2S)-(661470-52-6)
• EPA Substance Registry System: Morpholine, 2-(phenoxymethyl)-, (2S)-(661470-52-6)

Safety Data

• Hazardous Substances Data: 661470-52-6(Hazardous Substances Data)

Upstream product

• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 132073-83-7 (S)-morpholin-2-ylmethanol 
• 132073-82-6 (S)-4-Benzyl-2-(hydroxymethyl)morpholine 
• 1403506-15-9 (S)-1-benzyl-2-phenoxymethylmorpholine 
• 108-95-2 phenol 
• 71031-03-3 (R)-phenyl glycidyl ether 

Downstream Products

• 1403506-13-7 PL-225B 
• 1403506-14-8 (S)-ethyl 4-((2-carbamoyl-5-chloro-3-((2-(phenoxymethyl)morpholino)sulfonyl)-1H-indol-7-yl)amino)piperidine-1-carboxylate methanesulfonic acid 
• 1403506-16-0 (S)-4-((2-carbamoyl-5-chloro-3-((2-(phenoxymethyl)morpholino)sulfonyl)-1H-indol-7-yl)amino)-4-oxobutanoic acid 
• 1403506-23-9 (S)-3-(2-carbamoyl-5-chloro-3-(2-(phenoxymethyl)morpholinosulfonyl)-1H-indol-7-ylamino)propanoic acid 
• 1403506-25-1 (S)-7-((3-amino-3-oxopropyl)amino)-5-chloro-3-((2-(phenoxymethyl)morpholino)sulfonyl)-1H-indole-2-carboxamide 
• 1403506-26-2 (S)-5-chloro-7-((2-cyanoethyl)amino)-3-((2-(phenoxymethyl)morpholino)sulfonyl)-1H-indole-2-carboxamide 
• 1403506-27-3 (S)-5-chloro-3-((2-(phenoxymethyl)morpholino)sulfonyl)-7-((tetrahydro-2H-pyran-4-yl)amino)-1H-indole-2-carboxamide 
• 1403506-42-2 (S)-5-chloro-7-(cyclohexylamino)-3-((2-(phenoxymethyl)morpholino)sulfonyl)-1H-indole-2-carboxamide 
• 1403506-43-3 (S)-5-chloro-7-((cyclohexylmethyl)amino)-3-((2-(phenoxymethyl)morpholino)sulfonyl)-1H-indole-2-carboxamide 
• 1403506-46-6 (S)-5-chloro-7-((4-fluorobenzyl)amino)-3-((2-(phenoxymethyl)morpholino)sulfonyl)-1H-indole-2-carboxamide 
• 1403506-10-4 (S)-ethyl 5-chloro-7-nitro-3-(2-(phenoxymethyl)morpholinosulfonyl)-1H-indole-2-carboxylate 

Relevant articles and documents

Radiosynthesis and evaluation of 18F-labeled dopamine D4-receptor ligands

Introduction: The dopamine D4 receptor (D4R) has attracted considerable attention as potential target for the treatment of a broad range of central nervous system disorders. Although many efforts have been made to improve the performance of putative radioligand candidates, there is still a lack of D4R selective tracers suitable for in vivo PET imaging. Thus, the objective of this work was to develop a D4-selective PET ligand for clinical applications. Methods: Four compounds based on previous and new lead structures were prepared and characterized with regard to their D4R subtype selectivity and predicted lipophilicity. From these, 3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine I and (S)-4-(3-fluoro-4-methoxybenzyl)-2-(phenoxymethyl)morpholine II were selected for labeling with fluorine-18 and subsequent evaluation by in vitro autoradiography to assess their suitability as D4 radioligand candidates for in vivo imaging. Results: The radiosynthesis of [18F]I and [18F]II was successfully achieved by copper-mediated radiofluorination with radiochemical yields of 7% and 66%, respectively. The radioligand [18F]II showed specific binding in areas where D4 expression is expected, whereas [18F]I did not show any uptake in distinct brain regions and exhibited an unacceptable degree of non-specific binding. Conclusions: The compounds studied exhibited high D4R subtype selectivity and logP values compatible with high brain uptake, but only ligand [18F]II showed low non-specific binding and is therefore a good candidate for further evaluation. Advances in knowledge: The discovery of new lead structures for high-affinity D4 ligands opens up new possibilities for the development of suitable PET-radioligands. Implications for patient: PET-imaging of dopamine D4-receptors could facilitate understanding, diagnosis and treatment of neuropsychiatric and neurodegenerative diseases.

A PROCESS FOR THE PREPARATION OF MORPHOLINO SULFONYL INDOLE DERIVATIVES

The present invention relates to a process for the preparation of the compounds of formula (I) which are morpholino sulphonyl indole derivatives. The compounds of formula (I) are capable of inhibiting, modulating or regulating Insulin-Like-Growth Factor I